BrainChild Bio secures $119M Series A to advance CAR-T therapy for deadly pediatric brain tumor
BrainChild Bio announced a $119 million Series A financing round aimed at moving its CAR‑T programs for central nervous system cancers in children forward.
The company’s lead candidate, BCB-276, will enter a pivotal Phase 2 ILLUMINATE trial that plans to enroll 75 newly diagnosed diffuse intrinsic pontine glioma (DIPG) patients, with initial results expected in 2028.
DIPG is a rare, high‑grade brain tumor affecting roughly 300 U.S. children each year and is uniformly fatal, with radiation therapy the only current option.
BCB-276 is an autologous CAR‑T therapy that targets the B7‑H3 protein, which the company says is universally present on DIPG cells.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “BrainChild Bio targets deadly pediatric brain cancer with $116M series A”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that